Home > Journals > Gazzetta Medica Italiana Archivio per le Scienze Mediche > Past Issues > Gazzetta Medica Italiana - Archivio per le Scienze Mediche 2020 March;179(3) > Gazzetta Medica Italiana - Archivio per le Scienze Mediche 2020 March;179(3):99-103

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

ORIGINAL ARTICLE   

Gazzetta Medica Italiana - Archivio per le Scienze Mediche 2020 March;179(3):99-103

DOI: 10.23736/S0393-3660.20.04321-1

Copyright © 2020 EDIZIONI MINERVA MEDICA

language: English, Italian

The administration and monitoring of the edaravone medicinal specialty at the infusion center of P.O. San Giuliano ASLNA2NORD

Immacolata FILOSO 1 , Maria R. IACOLARE 1, Rosa IACONO 1, Tommaso DE ROSA 2, Nunzio QUINTO 2

1 U.O.S.D. F.cia P.O. San Giuliano AslNa2Nord, Naples, Italy; 2 P.O. San Giuliano AslNa2Nord, Naples, Italy



BACKGROUND: Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease of adulthood.
METHODS: The Italian Medicines Agency, AIFA, has approved the inclusion of the new drug Edaravone in the list of drugs that can be supplied by the NHS in compliance with law 648/96, the Campania Region has identified both the prescribing centers and those within the territory infusion. With reference to the ASLNa2Nord, the hospital unit designated to proceed with the infusion of the Edaravone molecule, is P.O. San Giuliano and the SLA referring clinician Dr. T. De Rosa neurology specialist.
RESULTS: All patients on both active and remote treatment did not experience any side effects during the infusion cycles.
CONCLUSIONS: Therefore we hope we will be able to give a positive answer to people with ALS who have been longer asking access to innovative drugs that represent a hope and a right for many families.


KEY WORDS: Rare diseases; Amyotrophic lateral sclerosis; Therapeutics

top of page